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ABSTRACT
Objective: Atrial ﬁbrillation (AF) is an important risk factor
for stroke. It is prevalent in approximately one-fourth of
stroke patients, and predictive of worse outcomes. This study
aimed to analyze the effect of AF on stroke-related inpatient
costs among ﬁrst-ever stroke patients in Sweden.
Methods: Hospitalizations and death records were moni-
tored for 3 years in 6611 ﬁrst-ever stroke patients. For stroke
as primary diagnosis, inpatient costs were calculated on the
basis of length of stay at different wards. For stroke as
secondary diagnosis, costs were based on diagnosis-related
groups.
Results: Patients with AF (24% of all patients) were older
(80 years vs. 73 years), had a higher prevalence of hyperten-
sion (49% vs. 41%) and/or diabetes (22% vs. 19%), higher
risk of experiencing a restroke, and higher case fatality rate
(43% vs. 25%) than patients without AF. The average cost
per patient over 3 years was €9004, with no statistically
signiﬁcant difference between AF and non-AF patients.
However, a multiple regression analysis showed that the pres-
ence of AF resulted in higher costs after considering a number
of background factors. Among patients surviving the index
event, AF patients had on average €818 higher inpatient
costs over 3 years than non-AF patients (€10,192 vs. €9374,
P < 0.01). The difference in costs was highest for patients
aged <65 years, with a difference of €4412 (P < 0.01).
Conclusion: AF-related strokes are associated with higher
3-year inpatient costs than non-AF strokes when controlling
for factors such as case fatality rates, other risk factors for
stroke, and age.
Keywords: cerebral hemorrhage, cerebral infarction,
cerebrovascular accident, health-care costs, risk factors,
stroke.
Introduction
Stroke is a major cause of morbidity and mortality in
industrialized countries and results in long-term dis-
abilities for survivors. In Sweden, the incidence rate of
stroke has been declining, but as the demographic
proﬁles change, the total number of persons affected
increases [1]. At the same time, the prognosis for sur-
viving stroke events has improved because of new tech-
nologies and rapid medical response with specialized
staff [1]. However, poststroke physical and mental
impairment for survivors is still a serious problem for
many patients [2,3]. Costs for stroke care therefore
extend beyond the acute phase. The total annual cost
of stroke care in Sweden has been estimated to be
€1.2 billion and €284 million in direct and indirect
costs, respectively (year 2000 price level) [4].
In 2001, the Riks-Stroke Collaboration estimated
that between 25,000 and 30,000 persons annually
suffer from stroke in Sweden. Roughly 50% of these
suffered from hypertension, one-fourth had atrial ﬁbril-
lation (AF), and 20% had diabetes [5]. Stroke patients
with AF have worse outcomes than those without AF,
including higher mortality, severity, recurrence rates,
and greater functional impairment and dependency
[6–8]. As a consequence, stroke costs may be higher in
AF patients than in non-AF patients. There is, however,
no published information on the costs of stroke speciﬁ-
cally for an AF population [6,7]. Cost-effectiveness
analyses of anticoagulation in patients with AF have
therefore used stroke costs for all stroke patients, which
may underestimate the cost beneﬁts of anticoagulation
for stroke prevention in AF [6,7].
The purpose of this study is to analyze the effect of
AF on stroke-related inpatient costs among ﬁrst-ever
stroke patients in Sweden over a 3-year period.
Data and Methods
Riks-Stroke, the Swedish national quality assessment
register for acute stroke, was established in 1994 to
monitor and to improve the quality of stroke manage-
ment by providing comparative feedback data on
process and outcome to each participating hospital
annually [9]. Since 1998, the register has covered all
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hospitals in Sweden admitting patients for acute stroke
care. A computerized data registration sheet is used
and local data are submitted by an internet-based
system to a national data management center. Almost
all patients with acute stroke in Sweden are treated in
hospitals during the acute phase [10]. The hospitals
have geographically based catchment areas that are
organized into 21 counties, each with at least one
county hospital. These counties are in turn organized
into six geographically based health-care regions, each
with a regional hospital that often also serves as a
university hospital.
We used an incidence-based approach where we
followed a cohort of ﬁrst-ever stroke patients reported
in the period of January 1, 2001 to June 30, 2001 until
December 31, 2003, which means that some patients
were censored, that is, we did not follow the patients
after December 31, 2003. Ethical approval of the study
was granted byNorrlandUniversityHospital (approval
No. 95-168). Stroke was deﬁned by the World Health
Organization (WHO) International Classiﬁcation of
Diseases (ICD)-10 codes I61, I63, and I64, although
patients with subarachnoid hemorrhagewere excluded.
The original patient data set from Riks-Stroke included
6824 patients diagnosed with a ﬁrst-ever (index) event.
In line with the WHO multinational monitoring of
trends and determinants in cardiovascular disease
project, the index event encompassed the ﬁrst 28 days
after the stroke onset and any re-strokes within that
period were considered part of the initial stroke [11].
Any consecutive length of hospitalization may,
however, extend beyond 28 days and still belong to the
index event. Patients were given a diagnosis of AF upon
admission to hospital if the electrocardiogram (ECG),
or an earlier ECG, showed AF or atrial ﬂutter. Informa-
tion about AF was missing in 213 patients (3.1%), who
were excluded from further analyses.
At the index event, the Riks-Stroke registry
recorded patient information such as living conditions
(at home, with or without assistance or institutional
living, e.g., a care home for the elderly), risk factors at
stroke onset (AF, treatment of hypertension, diabetes,
smoker), and stroke severity (according to the Reac-
tion Level Scale [RLS]-85) [12]. Any restroke events
in years 2001–2003 were taken from the Riks-Stroke
registry, whereas admissions with stroke as secondary
diagnosis, as well as the date of death, were taken from
the National Patient Registry at the National Board of
Health and Welfare. Hence, information on hospital-
izations and deaths between January 1, 2001 and
December 31, 2003 were recorded.
For all hospital events, data on inpatient length of
stay (LOS), type of ward, diagnosis-related group
(DRG) code, and associated DRG-weight were regis-
tered. Costs for the index event and restroke events
were calculated from the LOS and the per diem hos-
pital charges for each ward. Hospital ward charges for
year 2001 were taken from the Southern Region’s
Healthcare Board (see Supplementary material), which
comprised mainly wages, materials, and rent [13]. The
cost for computer tomography was added when appli-
cable. Costs for admissions with a secondary diagnosis
of stroke (i.e., stroke-related hospitalizations) were
calculated on the basis of their DRG-weights (€3988
per unit in 2001) [14].
The 3-year costs were calculated on the basis of all
patients who had experienced a ﬁrst-ever stroke and
included all primary and secondary stroke diagnosis
costs. Costs were discounted by 3% per annum and
expressed in 2001 euros (€) (€1 = SEK9.25 = US$0.90).
All statistical analyses were performed using SPSS for
Windows, version 12.0.2 (SPSS Inc., Chicago, IL). The
presented signiﬁcance levels resulted from the nonpara-
metric Mann–Whitney U-test, and a two-sided signiﬁ-
cance level (P < 0.05) was used to determine signiﬁcant
differences between the means. Cases with missing
observations were excluded from the analysis. To
analyze the determinants for costs, a linear regression
analysis was performed with logarithmically trans-
formed 3-year discounted inpatient costs as the depen-
dent variable. All variables in Table 1 were subject to a
stepwise forward variable inclusion on the basis of
coefﬁcient signiﬁcance level (Student’s t test: P < 0.05).
To capture the cost implications from the association
between AF, hypertension, and diabetes, interaction
terms for these variables were added [15]. All variables
were coded as dummy variables (condition present = 1
and 0 otherwise). For age and health-care region, the
age group older than 84 years and the southern health-
care region were used as reference categories. Because
the dependent variable was logarithmically trans-
formed, the deviation from unity of the exponentiated
coefﬁcient (Exp (b)) should be interpreted as the relative
effect that the presence of the studied variable has on
costs.
Results
Patient Characteristics
Of all 6611 patients, 1619 were diagnosed with AF
(Table 1). Patients with AF were older than nonAF
patients (80 years and 73 years, respectively), and their
stroke severity was higher when measured according
to the RLS scores “awake but sluggish” and “uncon-
scious.” In addition, both diabetes and hypertension
were more prevalent among the AF patients. Stroke
onset, regardless of presence of AF, occurred later in
life among women (76.7 years) than men (72.4 years).
There was great variation in stroke incidence between
health-care regions, but a signiﬁcant difference in the
distribution of AF and non-AF patients was detected
only in Uppsala-Örebro, where AF patients were less
frequent as a share of all the region’s stroke cases.
Women were more likely than men to have an AF
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diagnosis (26% and 23%, respectively, P = 0.01; not
presented in Table 1).
Case Fatality
The overall 3-year case fatality was 29%. As shown in
Figure 1 and Table 2, patients with AF had a statisti-
cally signiﬁcant higher case fatality (43%) than the
non-AF patients (25%) during the 3-year study period,
with odds ratios of around two for each year. Higher
3-year case fatality rates were also detected for diabetic
patients and nonsmokers, the latter probably a result
of the higher age of nonsmokers (76 vs. 67, P < 0.01).
Case fatality within the ﬁrst 28 days after the index
event was higher for patients with AF (13%) than
patients without AF (7%, P < 0.01) and for non-
smokers (8% vs. 5%, P < 0.01), but differences were
not seen for any of the other risk factors.
Inpatient Costs for All Patients
During the 3-year period, a total of 12,553 stroke-
related hospitalization events were recorded. Of these,
73% were due to index events, 11% due to re-strokes,
and 16% due to hospitalizations with stroke as sec-
ondary diagnosis. The mean number of hospitalization
days during the index event was 20.3, which translated
to €6918 per patient, with a minimum of €222 (one
inpatient day) and a maximum of €84,478 (257 con-
secutive inpatient days). Approximately 8% of the
patients experienced at least one restroke in the fol-
lowing 12-month period after the index event, with an
average cost of €8147 per patient (median: 4512). This
was higher than the index event cost, but patients
may have experienced more than one restroke in the
period. During the whole 3-year period, almost 12%
of the patients experienced at least one restroke. Total
3-year discounted inpatient costs, including index,
restroke, and other stroke-related costs, amounted to
Table 1 Patient characteristics of ﬁrst-ever stroke patients at the time of the ﬁrst attack
Characteristics
All patients
N = 6611
Non-AF
n = 4992
AF
n = 1619
P-value
AF vs. nonAF
Male sex 50.6% 51.8% 46.9% 0.001
Average age 74.5 72.8 79.7 <0.001
Age group (years)
<65 18.6% 22.9% 5.3% <0.001
65–74 23.1% 24.9% 17.5% <0.001
75–84 39.8% 37.3% 47.4% <0.001
>84 18.5% 14.9% 29.9% <0.001
Level of consciousness on admission to hospital
Awake but sluggish (RLS23) 12.5% 10.8% 17.9% <0.001
Unconscious (RLS48) 4.4% 3.9% 6.1% <0.001
Atrial ﬁbrillation 24.5% 0.0% 100.0% n.a.
Diabetes (risk factor) 19.8% 19.0% 22.3% 0.005
Hypertension (risk factor) 43.2% 41.2% 49.3% <0.001
Smoker (risk factor) 17.2% 19.0% 11.4% <0.001
Computer tomography 98.1% 98.4% 97.1% 0.001
Stroke-unit 74.6% 75.1% 73.1% 0.110
Need for home assistance 11.4% 9.9% 16.0% <0.001
Institutional living 6.5% 5.8% 8.7% <0.001
Health-care region
Northern Sweden 10.2% 10.4% 9.8% 0.487
Uppsala-Örebro 22.6% 23.2% 20.8% 0.049
Stockholm-Gotland 18.7% 18.3% 20.0% 0.143
Southwestern Sweden 19.1% 19.2% 18.8% 0.708
Southeastern Sweden 13.4% 12.9% 14.7% 0.068
Southern Sweden 15.7% 15.7% 16.0% 0.771
AF, atrial ﬁbrillation; n.a., not applicable; RLS, Reaction Level Scale.
Figure 1 Kaplan–Meier survival analysis of stroke patients, according to
presence of atrial ﬁbrillation (AF). Data beyond 1095 days (i.e., 3 years)
were censored.
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€9004 per patient (Table 2), and the average cost per
patient dying within the ﬁrst 28 days after the index
event was €3149 (median: 2529).
Inpatient Costs Stratiﬁed According to Presence of AF
Presence of AF implied longer inpatient stays at the
index event than for patients without AF (20.7 days
vs. 20.1 days, P < 0.01), and a higher frequency of
re-strokes during the 3-year period (15% vs. 13%,
P = 0.02). The discounted 3-year costs amounted to
€9281 for patients with AF and €8914 for patients
without a diagnosis of AF. Patients with diabetes and/or
hypertension had statistically signiﬁcant higher 3-year
costs than those without any of these risk factors
(Table 2). However, patients given a diagnosis of AF
had fewer total follow-up days because case fatality
during the index event was higher for these patients
than for patients with other risk factors. Therefore, we
also performed an analysis of cost differences for
patients who survived the index event (91%). For these
patients, the 3-year costs amounted to €10,192 and
€9374 for patients with and without AF, respectively
(Table 3). Costs were higher than those shown in
Table 2 as a result of both longer index event LOS
(22.4 days vs. 20.9 days, P < 0.01) and hospitalizations
due to primary and secondary stroke diagnosis during
the following 3 years. The case fatality rate among the
AF index event survivors was still higher than for any of
Table 2 Case fatality and average discounted inpatient costs (Euros) per patient during the 3-year study period according to sex and
risk factors, including index event mortality
n
Case fatality
(%) P-value
Average
cost (€) SD P-value
All patients
Year 1 6,611 18 Not applicable 8,105 9,044 Not applicable
Year 2 678 7 5,870 7,148
Year 3 418 7 4,709 4,106
All 3 years 6,611 29 9,004 10,035
Sex
Women 3,264 31 0.002 8,957 9,263 0.011
Men 3,347 27 9,050 10,736
Risk factor for stroke:
atrial ﬁbrillation
Yes 1,619 43 <0.001 9,281 9,434 <0.001
No 4,992 25 8,914 10,222
Risk factor for stroke:
diabetes
Yes 1,278 33 <0.001 9,949 10,169 <0.001
No 5,178 28 8,757 9,974
Risk factor for stroke:
hypertension
Yes 2,742 30 0.080 9,458 10,249 <0.001
No 3,612 28 8,559 9,758
Risk factor for stroke:
smoker
Yes 946 20 <0.001 9,463 12,461 0.173
No 4,561 29 8,990 9,395
n indicates the number of patients experiencing an inpatient event during the period.
The average costs for years 2 and 3 for all 6611 patients (intention-to-treat approach) can be computed as 5870 ¥ 678/6611 = 602 and 4709 ¥ 418/6611 = 298, respectively.
Table 3 Discounted 3-year inpatient costs in euros (€) (including index event, primary and secondary stroke diagnosis) and case
fatality for index event survivors according to presence of AF, year of follow-up, and age cohort
Year 1 Year 2 Year 3 All 3 years
<65 years
of age
65–74 years
of age
75–84 years
of age
>84 years
of age
AF patients n 1,401 204 92 1,401 80 262 670 389
Average cost (€) 9,012 5,817 5,079 10,192 13,981 10,573 10,369 8852
SD 8,875 5,451 3,978 9,787 17,724 11,000 9,245 6931
3-year case fatality 34% 10% 16% 32% 53%
Non-AF patients n 4,633 474 326 4,633 1,101 1,188 1,720 624
Average cost (€) 8,447 5,893 4,604 9,374 9,569 9,307 9,478 8873
SD (€) 9,423 7,770 4,141 10,451 13,305 10,395 9,127 7969
3-year case fatality 19% 6% 11% 24% 43%
P-value (costs) <0.001 0.179 0.128 <0.001 0.006 0.003 0.005 0.211
P-value (case fatality) <0.001 0.101 0.019 <0.001 0.001
n indicates the number of patients experiencing an inpatient event during the period.
The average costs for years 2 and 3 for all AF (1401) and nonAF (4633) patients are computed by weighting the cost by the fraction of patients experiencing a hospitalization
event, e.g., 5817 ¥ 204/1401 for AF patients in year 2.
AF, atrial ﬁbrillation.
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the other risk factors in Table 2, which included all
patients. Furthermore, patients with AF aged less than
65 years generated €4412 more in costs during the
3-year follow-up period than patients without AF, and
the difference in costs decreased with increasing age.
Linear Regression Analysis
The number of restrokes during the 3-year period was
the most important cost-driver (Table 4). Because the
reference category is patients without the condition,
their coefﬁcient would take the value of unity. The
coefﬁcient value of 2.195 for patients with one
restroke therefore indicates that costs are expected
to be 119.5% higher than for patients without any
re-strokes at all ((2.195–1.000) ¥ 100). Similarly,
patients with three or more re-strokes would generate
costs almost seven times more than patients with no
restrokes. Patients with AF or diabetes also generated
higher costs than patients without these comorbidities.
The only statistically signiﬁcant interaction term was
between AF and diabetes, which indicated that the
costs would be 14% higher for those having both
comorbidities than those without any comorbidity
(Exp(ln(1.111) + ln(1.179) + ln(0.868))). Patients
living at an institution (care home for the elderly
and/or disabled) reduced costs, especially among
patients with AF because they were 50% more likely to
be institutionalized (Table 1). Death during the index
event resulted in 65% lower costs, while death within
3 years yielded 32% higher costs. Hence, in contrast
to Table 3, patients under 75 years of age had approxi-
mately 10% lower costs than patients aged 85 years
and above (the comparator), when controlling for
these factors. Finally, costs varied between health-care
regions in Sweden, which may indicate geographic dif-
ferences in stroke treatment.
Discussion
The results presented in this study suggest that inpa-
tient costs for an average stroke patient are substantial:
€9000 during the ﬁrst 3 years after the ﬁrst-ever stroke
event. The case fatality rate among AF patients was
higher than for any other risk factor, which effectively
reduced the time period for which costs could have
been incurred. Patients with AF surviving the index
event were shown to demand more resources than
patients without AF. Hence, when studying cost impli-
cations for subgroups of patients (e.g., patients with
certain risk factors), it is important to consider poten-
tial excess case fatality rates.
The cost calculations were based on identical per
diem costs for all inpatient days spent at a given ward.
As a comparison, the Federation of Swedish County
Councils studied the cost per inpatient event and inpa-
tient days in the year 2001 [16]. They found that the
average per diem cost at the internal medicine ward
(including all diagnoses, not only stroke) at the Lund
University Hospital was €652. This is almost twice the
amount used in this analysis (€332). Furthermore,
we have attributed the full DRG cost for admissions
with stroke as a secondary diagnosis even though the
former stroke event may not entirely, nor uniquely, be
responsible for this latter admission. For these admis-
sions (16% of all admissions), it is likely that we
overestimated the costs. However, we did not account
for drugs, tests, surgeries, or any other medical proce-
dures during hospital care, nor did we include any
other resources consumed outside the hospital
(primary care, physiotherapists, transportation, pro-
duction losses), also, the third study-year was censored
for some patients. Hence, it might well be that we
underestimated the difference in costs between patients
with and without AF.
Our results are similar to those reported in a previ-
ous study on stroke patients in Sweden, where the
corresponding average 3-year discounted inpatient
cost amounted to €9187 in year 2000 prices [4].
However, that study used a different methodology
because it was based on DRG costs and therefore did
not consider the length of hospital stay. We have found
no study in the literature on inpatient care costs for AF
patients with which to compare our ﬁndings.
The regression model had rather low explanatory
power as indicated by the adjusted R2. However, given
Table 4 Determinants for 3-year costs: results from regression
analysis
Variable Exp (b) P-value
Constant 2584.292 <0.001
Age group (years)
<65 0.897 0.001
65–74 0.902 0.001
Risk factors
Atrial ﬁbrillation (AF) 1.111 0.001
Diabetes 1.179 <0.001
Interaction term:AF and diabetes 0.868 0.035
Number of restrokes during the
3-year period
1 2.195 <0.001
2 3.349 <0.001
3 or more 6.952 <0.001
Health-care region
Northern Sweden 1.086 0.041
Stockholm-Gotland 0.922 0.011
Southwestern Sweden 1.148 <0.001
Computer tomography 1.630 <0.001
Stroke-unit 1.147 <0.001
Institutional living 0.724 <0.001
Male sex 0.946 0.019
Death within 3 years 1.321 <0.001
Death at index event 0.347 <0.001
Awake but sluggish on admission to hospital 1.601 <0.001
Adjusted R2 0.211
Regression model: ln(C) = k + b1D1 + b2D2 + . . . , where C = 3-year discounted inpa-
tient costs, k = constant, bi = regression coefﬁcient, and Di = dummy variable.
Exp (b) is the antilog of the regression coefﬁcients. Patients older than 84 years and
the southern Sweden health-care region were used as comparators and were there-
fore excluded from the regression.
866 Ghatnekar and Glader
the cross-sectional patient register data at hand, this is
in line with what could be expected [17]. It is impor-
tant to note that logarithmically transformed values
are not directly re-transformable if the error term is
not normally distributed, unless a smear factor is used
[18]. Patient registers are seldom used for cost-of-
treatment studies, but rather, they are used to assess
the quality of the care provided. However, these regis-
ters can nonetheless be a useful source for studying
costs and outcomes, not least for decision makers.
Even though AF was seen to be more prevalent
among elderly patients, who in general have higher
mortality rates, the potential for primary prevention to
reduce the fatality rates is high. In a study by Glader
and colleagues at the Riks-Stroke Collaboration, it was
shown that only 11% of ﬁrst-ever stroke patients with
AF were treated with oral anticoagulants as primary
prevention [19]. Explanations for this underuse of oral
anticoagulants could be the variability in physicians’
beneﬁt–risk assessments and suboptimal organization
of primary care structures limiting access to anticoagu-
lation clinics [20–22].
The cost offset for increasing preventive measures
could be important. In a study on nonvalvular AF
patients in the UK, the total cost per patient per year
for stroke prophylaxis with warfarin was €262, includ-
ing costs for monitoring, hemorrhage, and production
losses [23]. Even though these UK results are not
directly transferable to a Swedish health-care setting,
they give an indication of the magnitude of the
resources needed for stroke prevention among AF
patients. Assuming that 1 (4%) of 25 treated patients
per annum avoids a stroke as a result of prophylaxis
[24], the cost per avoided stroke would be €6550. This
amount should be compared with the results in this
study with an average of €8100 for inpatient care in
the ﬁrst year after a ﬁrst-ever stroke.
Conclusion
AF-related strokes are associated with higher 3-year
inpatient costs than non-AF strokes when controlling
for factors such as case fatality rates, other risk factors
for stroke, and age.
Source of ﬁnancial support: Research grant provided by
AstraZeneca R & D, Sweden.
Supplementary material for this article (Appendix: Hospital
wards’ per diem costs) can be found at http://www.ispor.org/
publications/value/ViHsupplementary.asp
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